PT - JOURNAL ARTICLE AU - Halem, Michael TI - Correcting Covid-19 PCR Prevalence for False Positives in the Presence of Vaccination Immunity AID - 10.1101/2021.04.06.21255029 DP - 2021 Jan 01 TA - medRxiv PG - 2021.04.06.21255029 4099 - http://medrxiv.org/content/early/2021/05/02/2021.04.06.21255029.short 4100 - http://medrxiv.org/content/early/2021/05/02/2021.04.06.21255029.full AB - Since the first analysis was published on 7 April 2021 the PCR test positivity rate has dropped significantly below the then estimated false positive rate (FPR) of 1.16% using the exponential decay to FPR model. Therefore, the estimate has been rejected and a new model was developed.Using the ONS infection survey’s assumption (PCR FPR rate below 0.1%) the new model splits the test time series data into two periods based on a change in transmissibility that coincides with the reopening of England schools on 8 March. The new model provides for two base levels of exponential decay (for each period’s transmissibility) combined with a single decay rate increase dependent on vaccination.Because the FPR is relatively insignificant compared to current PCR test positives, it cannot be statistically separated using currently available England epidemic time series data by the non-linear least squares estimation technique. Therefore, the FPR factor is temporarily dropped in the least squares regression.The new model is stable in that it reasonably predicts through the most current available data (25 April) the future test prevalence using parameters estimated with 29 March data. Thus far, the estimate parameters remain within their original confidence intervals as successive days are added to the time series. Of potential usefulness is the current estimate for change in decay rate per mean vaccination rate, currently estimated at approximately 10.7% (CI: 8.8% - 12.6%). The estimate should be used with caution as other unforeseen factors could cause the model to misestimate.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding support. The author did this study independently without funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB - Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll code and data is on medRxiv under the supplementary-material link as a zip archive. See: https://doi.org/10.1101/2021.04.06.21255029